Why Submit an Abstract to the National Summit on Hematologic Cancers?

Submitting an abstract to the 2026 National Summit on Hematologic Cancers offers early-career investigators a unique opportunity to gain funding, publication, mentorship, and national recognition while shaping the future of hematology research.

In October 2026, Binaytara’s National Summit on Hematologic Cancers will once again take place in Nashville, Tennessee. This CE-accredited conference will enhance the knowledge and practice of oncology and hematology professionals, with a focus on the evolving management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The Summit’s program will provide updates on established therapies and introduce novel approaches, ultimately enabling conference attendees to make informed, patient-centered treatment decisions.

The Summit is still months away. But for early-career investigators and hematology fellows, the ramp-up to the National Summit on Hematologic Cancers is solidly underway: the Call for Abstracts is now live. Submitting an abstract marks the first step in a selection process that can lead to publication, high-visibility poster and oral presentation opportunities, and the chance to receive tens of thousands of dollars in funding.

The Impact Pitch: A High-Stakes Opportunity for Hematology Research Funding

Following in the footsteps of its sister summit SCHD (Binaytara’s flagship Summit on Cancer Health Disparities), the National Summit on Hematologic Cancers seeks to empower early-career investigators and medical fellows. The conference is offering multiple awards specifically targeted toward hematology fellows and hematologists within 10 years of completing their fellowships.

The awards will also be disseminated in the vein of SCHD: through the Impact Pitch. In this innovative, Shark Tank-style research award competition, early-career hematology investigators and fellows present their research proposals to a panel of judges. Medical professionals and the non-medical-professional public alike observe from the audience.

Whose research idea can change practice? And whose idea can sway public opinion? At the Impact Pitch, mentorship hones innovation, creating a comprehensive translation of research into real-world clinical benefit. At the National Summit on Hematologic Cancers, the audience and panel of judges will decide which projects receive the Shaji Kumar Hematology Research Award, a no-strings-attached merit-based award of up to $50,000. The Impact Pitch is powered by $150,000 in available award money, so multiple Impact Pitch presenters will walk away with funding.

Those who submit abstracts to the National Summit on Hematologic Cancers by August 15th at the latest will be eligible to present at the Summit and compete in the Impact Pitch for the Shaji Kumar Awards. Selected abstracts will also be published in the International Journal of Cancer Care and Delivery (IJCCD), Binaytara’s peer-reviewed oncology/hematology research journal.

Meet the Faculty: Leading Experts Driving Hematology Innovation

There’s no Shark Tank without the Sharks, and there’s no Impact Pitch without the Catalysts—the National Summit on Hematologic Cancers’ conference faculty. Hailing from all corners of the United States and the globe, The National Summit on Hematologic Cancers is honored to offer practice-changing and practice-defining hematology CME in partnership with all faculty, chairs, and committee members.

Dr. Navneet Majhail of Sarah Cannon Cancer Network, Dr. Nitin Jain of Anderson Cancer Center, Dr. Shaji Kumar of the Mayo Clinic, and Dr. Hetty Carraway of Cleveland Clinic will serve as Conference Chairs.

Additionally, City of Hope’s Dr. Vinod Pullarkat and Baylor College of Medicine’s Dr. Martha Mims will serve as Abstract Committee Chairs. Chairing the Scientific Review Committee are Dr. Parameswaran Venugopal (Rush University Medical Center), Dr. Jerald Radich (Fred Hutch), and Dr. Jorge Cortes (Georgia Cancer Center at Augusta University).

Top Reasons to Submit an Abstract to the 2026 Hematologic Cancers Summit

Binaytara is now accepting abstract submissions for the 2026 National Summit on Hematologic Cancers. If you’ve engaged in innovative hematology research, there’s no better stage to share your work—from funding opportunities to career growth, there are a host of reasons to submit your abstract now.

Mentorship Opportunities from Leading Hematology Experts

With world-class hematology faculty available at the Summit to offer feedback on abstracts, presentations, and research pitches (or just to strike up a conversation during the conference’s two-day runtime), the National Summit on Hematologic Cancers is a hub for mentorship and research advancement. Abstract submissions are reviewed by Abstract Committee Chairs and Members from internationally-recognized institutions, and accepted abstracts will be published in a peer-reviewed scholarly journal, the IJCCD.

Shape the Future of Hematology Research and Patient Care

The National Summit on Hematologic Cancers advances two of Binaytara’s programmatic goals: to reduce the burden of cancer through improving patient outcomes, and to empower cancer care professionals through providing high quality, accessible continuing medical education (CME) meetings across the United States. As one of hematology’s premier events, the Summit will gather hematologists and medical oncologists, fellows in both fields, advanced practice providers, oncology nurses, pharmacists, patient advocates, and other cancer care professionals—whose expertise will combine to create a forum that will establish the direction of future hematology research. Submit your abstract today to help shape the conversation.

Research Awards: Up to $50,000 Per Awardee in Funding Available

Finally, the research awards tied to the Summit exist to turn innovative potential into real impact, and to support the next generation of hematologists. If you are a hematology fellow or are within 10 years of completing your fellowship, the Shaji Kumar Hematology Research Awards—up to $50,000 per awardee—await you in Nashville.

Submit Your Abstract By August 15

The National Summit on Hematologic Cancers is taking place on October 16th-17th, 2026. Abstract submissions will be accepted through August 15th. The Summit welcomes encore submissions, provided they remain scientifically relevant and include appropriate disclosure of prior presentation(s). For more information about the abstract submission process and timeline, visit the Awards page. For more detailed information on submission criteria, or if you are ready to submit an abstract, visit the Submission page.

Frequently Asked Questions About Abstract Submission

1. Who should submit an abstract to the Summit?

Early-career hematologists, fellows, and researchers within 10 years of completing training are encouraged to apply.

2. What are the benefits of submitting an abstract?

Benefits include funding opportunities, publication in IJCCD, mentorship, and national exposure.

3. What is the Impact Pitch?

A Shark Tank-style competition where selected researchers present their ideas for funding and feedback.

4. What is the deadline for submission?

Abstracts must be submitted by August 15, 2026.